Document is current

Article History

Received: 28 July 2023

Accepted: 25 September 2023

First Online: 2 October 2023

Declarations

:

: The study was reviewed and approved by the Regional Ethical Committee (REC) for Research Ethics in Medicine and Health Sciences – Region North Norway (approval number 228765). Any future auditing of this study will be evaluated by the REC – Region North Norway. The exclusion criteria for this trial follow the latest safety recommendations for rTMS [] thereby reducing the risk of adverse events or reactions to iTBS to a minimum. A medical doctor will be responsible for the evaluation of the patient’s suitability for the study and the patient’s safety throughout the iTBS treatment schedule.Any serious adverse events will be reported to the Regional Research Ethics Committee and the University Hospital of North Norway immediately. If any participant suffers harm from participating in this study, they will receive medical treatment as required as a public patient.Serious adverse events will make unblinding permissible. A serious event will also stop the data collection until the reason for the event is clarified. The participant information materials and informed consent form are available from the corresponding author upon request.If a patient withdraws from the stimulation, the information collected prior to the withdrawal will be kept and used. If a patient withdraws his or her study consent, the information collected will not be used.

: Not applicable.

: All authors declare that they have no competing interests.